TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22182496
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with atrioventricular optimization (AVO) via SmartDelay or echocardiography
Study: 20517484
Drug: Rasagiline (as
Normalized name: rasagiline (as mesylate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (as monotherapy in early PD and adjunctive therapy in advanced PD)
Study: 12351443
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (hyperinsulinemic-euglycemic clamps at 1, 2, and 4 mU x min(‐1) x kg(‐1)) for 67 hours
Study: 10419923
Drug: IFN-ribavirin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-ribavirin (3 MU three times weekly + 1-1.2 g ribavirin daily for 6 months)
Study: 10419923
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy (3 MU three times weekly for 6 months)
Study: 7593730
Drug: moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (450 mg/day) plus thioridazine (100 mg/day)
Study: 7593730
Drug: moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (450 mg/day) plus placebo
Study: 2147500
Drug: Cefotetan 1
Normalized name: cefotetan 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 1 g intravenously
Study: 6407050
Drug: Bupropion (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300-600 mg/day)
Study: 29912723
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid and 0.9% saline solution
Study: 30345312
Drug: Curcumin-Galactomannoside Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin-Galactomannoside Complex (CGM) at 250 mg × 2/day for 8 weeks
Study: 20089009
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (4.6 mg/24 hr)
Study: 27687394
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation parameters with f=9 beats per minute, VT=8 mL/kg, I:E=1:2.0
Study: 22858430
Drug: Intravenous landiolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous landiolol at 5 μg/kg/min for 3 days (group L)
Study: 22858430
Drug: Oral bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisoprolol postoperatively with landiolol (group LB)
Study: 22858430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without beta-blocker therapy (group C)
Study: 20532141
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection (IVBI) 1.25 mg/0.05 mL
Study: 10388248
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg/kg/h
Study: 10388248
Drug: Lidocaine 2.5
Normalized name: LIDOCAINE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2.5 mg/kg/h
Study: 8739822
Drug: Quinidine bisulphate
Normalized name: quinidine bisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine bisulphate (250 mg)
Study: 8739822
Drug: Chlorpromazine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine hydrochloride (100 mg) with quinidine
Study: 8739822
Drug: Chlorpromazine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine hydrochloride (100 mg) without quinidine (control)
Study: 6129367
Drug: Sodium DL‐3‐hydroxybutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium DL‐3‐hydroxybutyrate administered during a 2.5 MJ (600 kcal) diet with 34 g protein and total fast (water and vitamins only) on alternate days for 21 days
Study: 6129367
Drug: Sodium DL‐3‐hydroxybutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium DL‐3‐hydroxybutyrate administered during therapeutic starvation for 14 days
Study: 1902657
Drug: Crystalloid solutions
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solutions
Study: 23842041
Drug: Sunitinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib therapy
Study: 24471663
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 2 g
Study: 16508386
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib 40 mg
Study: 24471663
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous paracetamol 2 g and intravenous parecoxib 40 mg
Study: 22937736
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (22.5 mg/kg twice daily) with placebo‐azithromycin
Study: 22937736
Drug: Azithromycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5 mg/kg daily) with placebo‐amoxicillin‐clavulanic acid
Study: 22937736
Drug: Placebo‐azithromycin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo‐azithromycin with placebo‐amoxicillin‐clavulanic acid
Study: 19895619
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for major depression over 18 months
Study: 19895619
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for major depression
Study: 18093298
Drug: Passive movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive movement therapy (PMT) given three times a week for four weeks.
Study: 16253086
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) spray
Study: 16253086
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride (B‐HCl) spray
Study: 16253086
Drug: Chlorhexidine plus
Normalized name: chlorhexidine Topical Solution [CHX Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine plus Benzydamine hydrochloride (CHX/B‐HCl) spray
Study: 9701431
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) with Aerochamber
Study: 2767766
Drug: Doxycycline 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 0.2 g with 300 ml of fresh milk
Study: 2767766
Drug: Doxycycline 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 0.2 g with 300 ml of water
Study: 48832
Drug: Educational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational programme aimed at instructing about hypertension and its treatment
Study: 15266196
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment
Study: 19723679
Drug: Pro-juven progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pro-juven progesterone cream, 20 mg twice daily
Study: 17784896
Drug: Unobserved dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unobserved dosing of buprenorphine-naloxone for 3 months
Study: 17784896
Drug: Observed dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observed dosing of buprenorphine-naloxone for 3 months
Study: 17784896
Drug: Unobserved dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unobserved dosing of buprenorphine-naloxone
Study: 17784896
Drug: Observed dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observed dosing of buprenorphine-naloxone
Study: 15569116
Drug: Bifidobacteria-fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria-fermented milk (100 mL/day for 12 weeks)
Study: 3107115
Drug: Lidocaine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (loading dose: 3 mg/kg body weight in 10 min; maintenance dose: 1 mg/kg in 20 min)
Study: 3107115
Drug: Tocainide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide infusion (750 mg in 30 min)
Study: 3107115
Drug: Tocainide orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide orally (400 to 2,400 mg per day)
Study: 16194311
Drug: Placebo (glycine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine) (0.5 g.kg(‐1).d(‐1) for 7 days)
Study: 12668699
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day)
Study: 8705743
Drug: Sequential argon
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential argon laser and Nd:YAG laser iridotomy
Study: 1679736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 6‐methylprednisolone (48 mg daily, tapered) and sulfasalazine (3 g daily) (n = 52)
Study: 6134042
Drug: Oral bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromocriptine (1.25 mg)
Study: 3542346
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of moxalactam 2 g intramuscularly
Study: 3542346
Drug: Three-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose regimen of cefoxitin (2 g intramuscularly on call, followed by 2 g intravenously every six hours for two additional doses)
Study: 25774090
Drug: Sufentanil target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil target-controlled infusion (TCI) at 0.1682 ng/ml
Study: 25774090
Drug: Sufentanil target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil target-controlled infusion (TCI) at various concentrations (0.19, 0.1809, 0.1723, 0.1641, 0.1563, 0.1489 ng/ml)
Study: 23062248
Drug: Massage (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage (twice-daily for 4 weeks by licensed massage therapists)
Study: 23062248
Drug: Control care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control care (twice-daily for 4 weeks)
Study: 16613928
Drug: i.v. acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. acetaminophen 15 mg kg(‐1)
Study: 16613928
Drug: i.m. meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. meperidine 1 mg kg(‐1)
Study: 8625373
Drug: Calcitonin (Calsynar),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks
Study: 8625373
Drug: Calcitonin (Calsynar),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks + oral collagen hydrolysate, 10 g per day for 24 weeks
Study: 8625373
Drug: Oral collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral collagen hydrolysate, 10 g per day for 24 weeks (after calcitonin treatment)
Study: 1351547
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (8 mmol over 5 min followed by 65 mmol over 24 h)
Study: 16432050
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg/day
Study: 3049338
Drug: Hydrochlorothiazide 100
Normalized name: hydrochlorothiazide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 100 mg/day
Study: 2870810
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus Bevantolol 400 mg/day
Study: 2870810
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (Hydrochlorothiazide + Bevantolol)
Study: 26111953
Drug: EGFRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFRI treatment
Study: 25653802
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment for 20 sessions of 20 minutes
Study: 19907299
Drug: 20-G standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-G standard PPV
Study: 19907299
Drug: 25-G transconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-G transconjunctival sutureless vitrectomy (TSV)
Study: 19907299
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 20-G and 25-G groups
Study: 18631166
Drug: Anaerobic storage
Normalized name: Peptostreptococcus anaerobius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 7 weeks of storage
Study: 18631166
Drug: Anaerobic storage
Normalized name: Peptostreptococcus anaerobius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 11 weeks of storage
Study: 16144170
Drug: Intraventricular administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraventricular administration of rt-PA (3 mg every 24 hours)
Study: 16144170
Drug: Intraventricular administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraventricular administration of rt-PA
Study: 12361993
Drug: Lumbar support
Normalized name: lumbar supports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar support used daily for the first week and on LBP days for the following 6 months
Study: 356240
Drug: Proquazone (3x300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (3x300 mg/day)
Study: 356240
Drug: Naproxen (2x250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (2x250 mg plus one placebo capsule/day)
Study: 30428474
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg bid for 3 months
Study: 30428474
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg bid combined with lactulose 30-60 mL daily for 3 months
Study: 30428474
Drug: Rifaximin therapy
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin therapy with and without lactulose
Study: 30428474
Drug: Rifaximin therapy
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin therapy
Study: 30218387
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house dust mite (HDM) allergen extract
Study: 23295594
Drug: Brazilian Cardioprotective
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian Cardioprotective Diet Program (weekly sessions with dietitians)
Study: 23295594
Drug: Usual dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual dietary therapy (Group B - weekly sessions with dietitian)
Study: 23295594
Drug: Usual dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual dietary therapy (Group C - monthly sessions with dietitian)
Study: 19531257
Drug: Whole-meal rye
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-meal rye bread (150 g)
Study: 19531257
Drug: White wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wheat bread (150 g)
Study: 11808763
Drug: Sugar-free chewing
Normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free chewing gum containing 0.19 mg of CPP-ACP
Study: 11808763
Drug: Sugar-free chewing
Normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free chewing gum containing 10.0 mg of CPP-ACP
Study: 11808763
Drug: Sugar-free chewing
Normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free chewing gum containing 18.8 mg of CPP-ACP
Study: 11808763
Drug: Sugar-free chewing
Normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free chewing gum containing 56.4 mg of CPP-ACP
Study: 7832578
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g elemental calcium (control)
Study: 7832578
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g elemental calcium
Study: 7832578
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g elemental calcium
Study: 8817407
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg, sublingual)
Study: 27172664
Drug: Skin wound
Normalized name: POLOXAMER 188 200 mg in 1 mL TOPICAL LIQUID [Shur Clens Skin Wound Cleanser 24 Count Single Dose Ampules]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin wound induction gel
Study: 15679765
Drug: Wireless pH
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless pH capsule
Study: 7717486
Drug: Pethidine (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (0.85 mg.kg‐1)
Study: 7717486
Drug: Lignocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (1 mg.kg‐1)
Study: 1972833
Drug: PUVA photochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA photochemotherapy (oral 8‐MOP followed by UV‐A from Philips TL‐09)
Study: 381921
Drug: Piadar lotion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piadar lotion, applied 2 to 3 times daily for four weeks
Study: 381921
Drug: Tolnaftate solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolnaftate solution, applied 2 to 3 times daily for four weeks
Study: 24818542
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous ondansetron
Study: 28956529
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (1 mg/kg)
Study: 24092829
Drug: High-phosphate diet
Normalized name: hydroxypropyl distarch phosphate, high amylose corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phosphate diet (1800 mg/d) for 6 days
Study: 19307106
Drug: AZI-IR 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZI-IR 500 mg
Study: 17702589
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion starting in the operating theatre (Group OT)
Study: 17702589
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion starting in the ICU (Group ICU)
Study: 15080773
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration (both doses)
Study: 11343562
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of milrinone (5 microg/kg/min)
Study: 11343562
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without milrinone
Study: 9806580
Drug: Beta2 glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta2 glycoprotein I IgM antibody and antinuclear antibody
Study: 1096388
Drug: Once-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E1R1)
Study: 1096388
Drug: Twice-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E2R2)
Study: 1096388
Drug: Initial inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial inpatient phase of rifampicin 600 mg and ethambutol 25 mg/kg daily for 12 weeks
Study: 26562379
Drug: Wound Gel
Normalized name: Hylase Wound Gel
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wound Gel
Study: 26562379
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care plus Wound Gel (SOC + gel)
Study: 21111078
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose teriparatide (20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months)
Study: 21111078
Drug: Constant dose
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dose teriparatide (30 μg daily for 18 months)
Study: 16273395
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication on
Study: 16273395
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication off
Study: 16273395
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus (STN) stimulation off with low medication (usual dose)
Study: 16273395
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus (STN) stimulation off with high medication (suprathreshold dose)
Study: 16273395
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus (STN) stimulation on with low medication (usual dose)
Study: 8088206
Drug: Portal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portal infusion with Mitomycin‐C (MMC) and 5‐Fluorouracil (5‐FU) starting immediately after operation